YaoGeJu

YaoGeJuCDE public lists · weekly counts

National Drug-Review Weekly

The available CDE acceptance records list 9 drug applications between 4 August 2023 and 10 August 2023 (data as of 13 November 2026 06:00). Of these, generic applications numbered 1, covering 1 drug name.

2023/08/04 – 2023/08/10

Period
2023/08/04 to 2023/08/10, 7 days inclusive
Data as of
2026/11/13 06:00
Cached records
94,806 acceptance records, 11,656 under review now
Source
Public data from the CDE acceptance list and under-review list
New acceptances this week
9
Drugs with new generic filings (by drug name, de-duplicated)
1
Accepted this week, now under review
0

DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.

Names with a public page are linked.

New acceptances this week

By application type and drug type

9filings, 1 of them generic

By application type

Application typeFilings
Supplement7
Generic1
New drug1

By drug type

Drug typeFilings
Therapeutic biologic4
Chemical drug3
TCM2

DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.

Most new generic filings, by drug

1 drug with new generic filings

#DrugNew generic filingsFiling companiesUnder review, all years
1Salbutamol Sulfate injection111

DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.

Most new acceptances, by company

7 companies with new acceptances; top 10 listed

#Company (first applicant)FilingsDrugsGeneric
1Guangzhou Bai Ji Shen Zhou Biopharmaceutical Co., Ltd. romanized220
2You Shi Bi (Zhuhai) Pharmaceutical Co., Ltd. romanized210
3Roche Registration GmbH110
4Hua Tuo Guo Yao Co., Ltd. romanized110
5Sichuan Guo Rui Pharma Co., Ltd. romanized111
6Ming Ji Biopharmaceutical (Beijing) Co., Ltd. romanized110
7Xian Qian He Pharma Co., Ltd. romanized110

DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.

Under-review list changes

Compared across this platform's snapshots of the under-review list

Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.

DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.

Class 3 and new-drug acceptances

2 this week

AcceptedDrugApplicants
2023/08/10Generic · Class 3 Salbutamol Sulfate injectionCYHS2302079 Sichuan Guo Rui Pharma Co., Ltd. romanized
2023/08/10New drug · Class 1 M108单抗注射液 · No verified English nameCXSL2300537 Ming Ji Biopharmaceutical (Beijing) Co., Ltd. romanized

DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.

Subscribe to the weekly

No account needed.

The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.